Pharmaceutical News

RSS

Salix Pharmaceuticals announces availability of Xifaxan tablets for reducing risk of overt HE recurrence

Salix Pharmaceuticals, Ltd. today announced the availability of Xifaxan (rifaximin) 550 mg tablets for the reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. Those HE patients may now fill their Xifaxan 550 mg prescriptions in U.S. pharmacies and should speak with their doctors about this important treatment option.

24 May 2010

Ortho-McNeil Pharmaceutical pleads guilty for promoting epilepsy drug Topamax for psychiatric use

Ortho-McNeil Pharmaceutical LLC, a subsidiary of Johnson & Johnson, pled guilty today in U.S. District Court in Boston to one count of misdemeanor violation of the Food, Drug & Cosmetic Act for illegally promoting its epilepsy drug Topamax for uses that were not approved by the FDA. The company was also sentenced at today's hearing.

24 May 2010

Filing of Clinical Data's NDA for vilazodone accepted for FDA review

Clinical Data, Inc., today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application for vilazodone for the treatment of major depressive disorder.

24 May 2010

NCC receives $25,000 grant award from Hospira Foundation to support pharmaceutical relief program

The National Cancer Coalition is pleased to announce that it recently received a $25,000 grant award from the Hospira Foundation, the philanthropic arm of Hospira, Inc., to support its pharmaceutical relief program within the Dominican Republic. NCC is seeking to significantly increase the levels of medical resources that it provides to the public hospitals of the Dominican Republic in an effort to more fully treat the country's underserved patients, and this grant will contribute toward achieving that goal.

24 May 2010

New findings on INTUNIV Extended Release Tablets presented at major psychiatric meeting

Shire plc, the global specialty biopharmaceutical company, today announced new findings on once-daily INTUNIV (guanfacine) Extended Release Tablets, the first selective alpha-2A agonist approved for the treatment of Attention Deficit Hyperactivity Disorder, at a major psychiatric meeting.

24 May 2010

New therapies can turn cancer into chronic disease

Two new studies suggest that the prolonged use of cancer drugs helped stunt the progress of the disease, a shift from the scheduled courses of treatment typically delivered to patients, The Wall Street Journal reports.

24 May 2010

Research on new types of anti-HIV drugs presented at International Microbicides Conference

Researchers testing a vaginal microbicide based on a new type of anti-HIV drug found it provided monkeys significant protection against infection with a virus similar to HIV, according to a study reported at the International Microbicides Conference in Pittsburgh today.

24 May 2010

Researchers test NicVAX vaccine to help people quit smoking, avoid relapses

In a unique twist to a decades-old health crisis, Michigan State University researchers are testing a new vaccine to help people quit smoking and avoid relapses.

21 May 2010

Updates on Micromet's BiTE antibody development programs to be made at two medical conferences

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that updates on several of its BiTE antibody development programs will be made at two upcoming medical conferences.

21 May 2010

Dr. Reddy's Laboratories launches tacrolimus capsules in the US market

Dr. Reddy's Laboratories today announced that it has launched tacrolimus capsules, (0.5mg, 1mg, 5mg), a bioequivalent generic version of Prograf Capsules, in the US market on May 20, 2010. The United States Food & Drug Administration granted an approval of Dr. Reddy's ANDA for tacrolimus capsules on May 13, 2010.

21 May 2010

Vitacost.com announces expansion of operations in North Carolina

Vitacost.com, Inc., a leading online retailer and direct marketer of health and wellness products, today announced the groundbreaking for the expansion of its east coast manufacturing and distribution facility in Lexington, North Carolina.

21 May 2010

IGF1 drug improves nerve cell communication in PMS mouse model

Researchers from Mount Sinai School of Medicine have identified a drug that improves communication between nerve cells in a mouse model of Phelan-McDermid Syndrome (PMS).

21 May 2010

Common misconceptions about general anesthesia

Eight-five per cent of patients who took part in a survey shortly after day surgery said that they had been anxious about receiving a general anaesthetic, according to research in the May issue of the Journal of Advanced Nursing.

21 May 2010

Influenza antiviral drugs not hoarded during recent H1N1 flu season, says Prime Therapeutics

Despite concerns from public health officials, influenza antiviral drugs were not hoarded during the recent H1N1 flu season, according to a new analysis presented recently at the Academy of Managed Care Pharmacy's 22nd Annual Meeting in San Diego by Prime Therapeutics (Prime), a thought leader in pharmacy benefit management.

21 May 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Pfizer Oncology will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology meeting in Chicago from June 4-8.

21 May 2010

Sorrento Therapeutics receives STTR grant to develop antibody therapeutics to combat MRSA

Sorrento Therapeutics, Inc. today announced that it has received an Advanced Technology Small Business Technology Transfer Research grant from the National Institute of Allergy and Infectious Diseases. The peer-reviewed grant was awarded to support the Company's program to generate and develop novel antibody therapeutics and vaccines to combat Staphylococcus aureus infections, including methicillin-resistant S. aureus, by disrupting quorum sensing, a bacterial communication process essential to virulence.

21 May 2010

Genentech to present new data for targeted cancer medicines at 46th ASCO

Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents across 30 cancer types will be presented during the meeting that is taking place June 4 to 8, 2010 in Chicago.

21 May 2010

Americans divided over nation’s drug approval process

Nearly three-quarters of Americans are confident in our system for reviewing the effectiveness and safety of new medicines and medical devices, yet 41% say it takes too long to approve a drug and allow it to be sold to consumers.

21 May 2010

VIA-2291 can reduce inflammation in patients with atherosclerosis: Study

The results of a major clinical study carried out at the Montreal Heart Institute by Dr. Jean-Claude Tardif are now available in the journal Circulation Cardiovascular Imaging. Dr. Tardif is a cardiologist and director of the MHI Research Centre, as well as a professor in the faculty of medicine and holder of the atherosclerosis research chair at the Universit- de Montr-al.

21 May 2010

Salix announces additional intellectual property protection for rifaximin in treatment of IBS

Salix Pharmaceuticals, Ltd. today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,718,608. This patent provides protection until August 2019 for rifaximin, which Salix markets in the United States under the trade names XIFAXAN® (200mg) and XIFAXAN550™ (550mg).

21 May 2010

Pharmaceutical News

Salix Pharmaceuticals announces availability of Xifaxan tablets for reducing risk of overt HE recurrence

Ortho-McNeil Pharmaceutical pleads guilty for promoting epilepsy drug Topamax for psychiatric use

Filing of Clinical Data's NDA for vilazodone accepted for FDA review

NCC receives $25,000 grant award from Hospira Foundation to support pharmaceutical relief program

New findings on INTUNIV Extended Release Tablets presented at major psychiatric meeting

New therapies can turn cancer into chronic disease

Research on new types of anti-HIV drugs presented at International Microbicides Conference

Researchers test NicVAX vaccine to help people quit smoking, avoid relapses

Updates on Micromet's BiTE antibody development programs to be made at two medical conferences

Dr. Reddy's Laboratories launches tacrolimus capsules in the US market

Vitacost.com announces expansion of operations in North Carolina

IGF1 drug improves nerve cell communication in PMS mouse model

Common misconceptions about general anesthesia

Influenza antiviral drugs not hoarded during recent H1N1 flu season, says Prime Therapeutics

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Sorrento Therapeutics receives STTR grant to develop antibody therapeutics to combat MRSA

Genentech to present new data for targeted cancer medicines at 46th ASCO

Americans divided over nation’s drug approval process

VIA-2291 can reduce inflammation in patients with atherosclerosis: Study

Salix announces additional intellectual property protection for rifaximin in treatment of IBS

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News